Pomerantz Law Firm Investigates MiMedx Group, Inc. for Potential Securities Fraud
Pomerantz LLP is investigating MiMedx Group, Inc. (NASDAQ: MDXG) for potential securities fraud following disappointing Q1 2026 financial results and a significant drop in stock price. The firm reported a 33.1% year-over-year revenue decline and lowered full-year sales expectations due to new Medicare reimbursement policies affecting the wound care market.
Topics: financial results regulatory investigation securities fraud stock price drop